GIGABYTE
GIGABYTE is joining CES Virtual with its website extension – INDUSTRY – to present products and solutions that propel digital transformation in industries such as 5G & telecom, automotive, creative & gaming, data centers , manufacturing, and retail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005431/en/
GIGABYTE takes pride in having an incredibly deep portfolio of enterprise products that support cloud, edge, and data centers. There are over 75 servers for AMD EPYC CPU alone, as well as Intel Xeon Scalable CPU, and over 10 servers for Ampere Altra CPU, and not to forget over 20 server motherboards. GIGABYTE offers edge servers developed based on Arm architecture. These high-density Arm servers , using Ampere’s massive 80 / 128 core CPU, provide the performance, storage, network, and above all, the flexibility to be deployed for the next generation of telecommunications where processing work needs to be done on-site. GIGABYTE’s server solutions are also applicable to various industries, and are highly valued by large and small high-tech companies, medical, scientific, academic research, and public institutions, etc., and have successfully assisted them in innovation and breakthroughs in their fields.
Our industries are undergoing an invigorating metamorphosis as AI, HPC, IoT, and other breakthroughs bring about a paradigm shift. MyelinTek Inc., an investee company of GIGABYTE developed a deep learning system MLSteam, which includes optimized AI software stacking and comprehensive management tools in a user-friendly interface to make it easier for scientists to train and develop AI integration for autonomous vehicles. With the rapid development of Advanced Driver Assistance Systems (ADAS ) technology, GIGABYTE designs decision-making control units for different types of autonomous vehicles, as well as customized products such as ADAS ECUs, TCUs, assisting vehicles designers to develop their ideal products and improve the automotive industry.
GIGABYTE has years of proven experience in embedded computers and brought its latest generation of embedded systems to increase the operability of storage, logistic, and manufacturing facilities while lowering labor and management costs with the innovation of AGV, AMR, and Industrial Automation Security System. In the post-pandemic era, GIGABYTE’s embedded solutions integrated with AI and IoT technology helped automate the operation and management of open space rentals, allowing such new services to flourish.
GIGABYTE’s reputation to invent top-notch products with innovative VRM and thermal design makes the task to optimize overclocking performance on the latest Intel® Core™ CPUs easy and effective. The Z690 series motherboards provide beyond the essential features and power for both professional creators and gamers alike. Performance is the key to both immersive gameplay and smooth workflow, and GIGABYTE has taken performance above all else with this generation’s AORUS gaming laptops and the AERO creator laptops which are to be released in early 2022.
GIGABYTE has recently launched INDUSTRY to demonstrate its most pivotal products and solutions for different industries. One of the biggest highlights of the platform is its live chat function. GIGABYTE has arranged experts, who have keen insights on the industries, to standby the live chat and answer questions and inquiries made by CES visitors and buyers as they would at the physical venue. The live chat uses AI-generated avatars to show the status of its live experts, and also as a way to embrace the ‘metaverse ’ where virtual merges with reality. The INDUSTRY platform will host all products and solutions GIGABYTE is presenting at CES including trendy topics highlighted in the event and more. GIGABYTE welcomes all visitors to connect through this digital platform and see their industries from different perspectives.
INDUSTRY: https://industry.gigabyte.com
Visit GIGABYTE on CES Digital: https://gbte.tech/ces2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005431/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom